After six months of treatment, 19% of trial participants on GSK’s drug had no detectable hepatitis B for 24 weeks off treatment.

GSK's bepirovirsen (HIBSAGO) received FDA approval for chronic hepatitis B (CHB) treatment, showing 19% functional cure rates in trials. The six-month treatment can be administered at home after the first dose. GSK licensed the drug from Ionis in 2019, with Ionis eligible for milestone payments and royalties. CHB affects approximately 1.7 million people in the U.S.

Hutchmed (00013.HK) finalized a licensing deal with GSK for its KRAS-EGFR conjugate therapy, HMPL-A830. GSK gains global rights (excluding Greater China) for $110M upfront, with up to $1.185B in milestones. Hutchmed leads Phase I trials, while GSK handles later stages. The drug targets cancers with KRAS mutations, currently in early clinical testing.

GSK's depemokimab (Exdensur) showed significant improvements in asthma patients' quality of life, with benefits seen as early as 4 weeks and persisting through 52 weeks, according to a study presented at the CHEST Annual Meeting. The treatment was administered subcutaneously twice a year, with 363 patients receiving 100 mg doses and 196 on placebo. Mean changes in symptom, activity, and impact scores on the St.

GSK (NYSE: GSK) received FDA approval for Hibsago, a treatment for chronic hepatitis B. The company offers a 3.49% dividend yield with a 39% payout ratio and a 2.5% 3-year dividend growth rate. GSK's stock is trading at $50.63, 9.8% above its GF Value of $46.13. The company has a GF Score of 77/100, indicating solid financial health and valuation.

GSK plc (GSK) received FDA approval for Hibsago (bepirovirsen) to treat certain adult chronic hepatitis B patients. The drug is approved for use with NrtI therapy in patients without cirrhosis and with HBsAg ≤3000 IU/mL, following at least 6 months of NrtI treatment and suppressed HBV DNA. This marks GSK's second country approval for the drug, following Japan.

GSK PLC announced FDA approval of Hibsago (generic name bepirovirsen) for chronic hepatitis B treatment. The drug, a first-in-class antisense oligonucleotide, showed 19% functional cure rates in trials. GSK shares closed up 0.7% at 1,868.50 pence in London. The approval was granted under priority review and breakthrough therapy designation, according to the company.